Fate Therapeutics Inc Interim Phase 1 Clinical Data for AML Programs Corporate Call Transcript
Thank you all for joining us this afternoon. We are excited to share with you today interim Phase I clinical data for our FT516 and FT538 off-the-shelf iPSC-derived NK cell programs in relapsed/refractory acute myeloid leukemia.
Please note, as we discuss our FT516 and FT538 programs today, including clinical data and future plans for the programs, our comments will include forward-looking statements. These statements involve risks and uncertainties. And if I refer -- and I refer you to our most recent Form 10-Q filed with the SEC for a full disclosure of these risks and uncertainties. Note that undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. And the facts and circumstances underlying these forward-looking statements may change.
Before we begin today, I would like to thank Dr. Jeff Miller for joining us this afternoon. Dr. Miller is Professor of Medicine at the University of Minnesota and the Deputy Director of the Masonic Cancer Center. He
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |